PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

UBC-VCH scientists use drug to repair rare birth defect

Success in mouse model is first instance of drug reversing a congenital deformity

2013-12-20
(Press-News.org) Contact information: Brian Lin
brian.lin@ubc.ca
604-822-2234
University of British Columbia
UBC-VCH scientists use drug to repair rare birth defect Success in mouse model is first instance of drug reversing a congenital deformity

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

They formulated the drug Ataluren into eye drops, and found that it consistently restored normal vision in mice who had aniridia (ANN-uh-ridee- uh), a condition that severely limits the vision of about 5,000 people in North America. A small clinical trial with children and teens is expected to begin next year in Vancouver, the U.S. and the U.K.

Aniridia is caused by the presence of a "nonsense mutation" – an extra "stop sign" on the gene that interrupts production of a protein crucial for eye development. Aniridia patients don't have an iris (the coloured ring around the pupil), and suffer many other eye abnormalities.

Ataluren is believed to have the power to override the extra stop sign, thus allowing the protein to be made. The UBC-VCH scientists initially thought the drug would work only in utero – giving it to a pregnant mother to prevent aniridia from ever arising in her fetus. But then they gave their specially formulated Ataluren eye drops, which they call START, to two-week-old mice with aniridia, and found that it actually reversed the damage they had been born with.

"We were amazed to see how malleable the eye is after birth," said Cheryl Gregory-Evans, associate professor of ophthalmology and visual sciences and a neurobiologist at the Vancouver Coastal Health Research Institute. "This holds promise for treating other eye conditions caused by nonsense mutations, including some types of macular degeneration. And if it reverses damage in the eye, it raises the possibility of a cure for other congenital disorders. The challenge is getting it to the right place at the right time."

A video about the study is available at http://youtu.be/L9Gx1bUxCUg.

BACKGROUND | A POTENTIAL CURE FOR ANIRIDIA

Bad vision at birth, worse vision later: Aniridia is apparent at birth because of the missing iris. Toddlers with aniridia need eyeglasses to see, sunglasses or darkened contact lenses to protect their eyes from overexposure to light, and cannot read small text. Their eyes are continually moving, making it difficult for them to focus, and have higher internal pressure (glaucoma), which damages the optic nerve as they get older. They are also prone to corneal damage in their teens and early adulthood. Eventually, most people with aniridia are considered legally blind, and must resort to Braille or expensive electronic aids to read.

The plasticity of the eye: The reversal of tissue damage in young mice, published online today by the Journal of Clinical Investigation, fits with the fact that mammals' eyes aren't fully formed at birth. Human babies don't discern colours until they are six months old, and their depth perception isn't fully developed until the age of five.

Nonsense suppressor: Ataluren, made by the New Jersey-based PTC Therapeutics, is thought to be a "nonsense suppressor" – it silences the extra "stop codon" on the gene and allows a complete protein to be assembled. The drug is currently being tested as a treatment for cystic fibrosis and Duchenne muscular dystrophy, which are also caused by nonsense mutations.

A gritty solution: Gregory-Evans' first attempt at creating Ataluren eye drops proved unsuccessful. The drug didn't dissolve, and thus irritated the mice's eyes. So she turned to Kishor Wasan, a professor and associate dean in the Faculty of Pharmaceutical Sciences, who ground the drug into a very fine powder and combined it with a solution that adhered better to the eye.

A multidisciplinary team: Gregory-Evans also collaborated with her husband, Kevin Gregory-Evans, the Julia Levy BC Leadership Chair in Macular Research and an ophthalmologist at the VCH Eye Care Centre, who treats B.C. patients with aniridia. He administered the vision tests for the mice used in the study.

Clinical trial: The forthcoming clinical trial, involving about 30 patients, will be led by Gregory-Evans in Vancouver, and is being supported by the Vision for Tomorrow Foundation, a U.S.-based charity focused on aniridia and albinism (an absence of pigmentation in skin, hair and eyes that results in poor vision). If START is proven to be safe and effective, children with aniridia would use the drops twice a day for the rest of their lives. The drug would probably not reverse the condition in adults because their eyes would already be damaged beyond repair.



INFORMATION:

Funding from a UBC alumna: Cheryl Gregory-Evans' position and this research were funded by the Sharon Stewart Testamentary Trust. Stewart, of Victoria, was born with aniridia, and at the time of her graduation from UBC in 1968, she only had five per cent of her vision. She died in 2008 and donated over $6 million to UBC for aniridia research.



ELSE PRESS RELEASES FROM THIS DATE:

Enlisting cells' protein recycling machinery to regulate plant products

2013-12-20
Enlisting cells' protein recycling machinery to regulate plant products New molecular tools for controlling production of compounds important for flavors, human health, and biofuels UPTON, NY--Scientists at the U.S. Department of Energy's Brookhaven ...

New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells

2013-12-20
New mechanism that permits selective capture of microRNAs in nanovesicles that shuttle between cells The study presents the first description of a set of related nuceleotide sequences essential for the role of these small molecules in ...

More mentions in the FT linked to greater popularity of stocks

2013-12-20
More mentions in the FT linked to greater popularity of stocks A 6-year study of the Financial Times has found that the more frequently a company is mentioned in the newspaper in the morning, the greater the volume of shares traded in that company during the ...

Efforts to curb climate change require greater emphasis on livestock

2013-12-20
Efforts to curb climate change require greater emphasis on livestock CORVALLIS, Ore. – While climate change negotiators struggle to agree on ways to reduce carbon dioxide (CO2) emissions, they have paid inadequate attention to other greenhouse gases associated ...

Birth of black hole kills the radio star

2013-12-20
Birth of black hole kills the radio star Research clears telescope, disproves long-held theory Astronomers led by a Curtin University researcher have discovered a new population of exploding stars that "switch off" their radio transmissions before collapsing ...

An earthquake or a snow avalanche has its own shape

2013-12-20
An earthquake or a snow avalanche has its own shape However, it is crucial what one observes – paper fracture or the avalanching of snow. The results were just published in the Nature Communications journal. Avalanches of snow or earthquakes can be described in other ...

Smooth or grainy?

2013-12-20
Smooth or grainy? A SISSA paper reviews research on the grain of space-time Smooth" or grainy? Is space-time continuous or is it made up of very fine (10-35 metres on the "Planck scale") but discrete grains, if we look at it very ...

IRB develops ChroGPS, a new generation visual browser of the epigenome

2013-12-20
IRB develops ChroGPS, a new generation visual browser of the epigenome This is a software application that provides easily interpretable maps from which to analyse and understand the immense volume of epigenetic and genetic ...

Birth control at the zoo

2013-12-20
Birth control at the zoo Vets meet the elusive goal of hippo castration Common hippopotami (Hippopotamus amphibius) are vulnerable to extinction in the wild, but reproduce extremely well under captive breeding conditions. Females ...

Breaking down cancer's defense mechanisms

2013-12-20
Breaking down cancer's defense mechanisms A possible new method for treating pancreatic cancer which enables the body's immune system to attack and kill cancer cells has been developed by researchers. The method uses a drug which breaks down the ...

LAST 30 PRESS RELEASES:

Korea University study identifies age 70 as cutoff for chemotherapy benefit in colorectal cancer

Study explores brain cell communication called ‘crosstalk’

4 beer and wine discoveries

Massage Therapy Foundation awards $299,465 research grant to Children’s Hospital of Philadelphia

Chung-Ang University develops chloride-resistant Ru nanocatalysts for sustainable hydrogen production from seawater

Afghanistan’s August 2025 earthquake reveals the cost of international isolation, UN scientists warn

Shortlist announced for Panmure House Prize

Small nuclear RNA base editing a safer alternative to CRISPR, UC San Diego researchers find

Can Hayabusa2 touchdown? New study reveals space mission’s target asteroid is tinier and faster than thought

Millisecond windows of time may be key to how we hear, study finds

Graz University of Technology opens up new avenues in lung cancer research with digital cell twin

Exoplanets are not water worlds

Study shows increasing ‘healthy competition’ between menu options nudges patients towards greener, lower-fat hospital food choices

New insights into melanoma plasticity uncover a critical role of iron metabolism

A graphene sandwich — deposited or transferred?

New light-powered motor fits inside a strand of hair

Oil rig study reveals vital role of tiny hoverflies

Children’s Hospital of Philadelphia researchers boost widespread use of dental varnish across pediatric network

iRECODE: A new computational method that brings clarity to single-cell analysis

New NUS-MOH study: Singapore’s healthcare sector carbon emissions 18% lower than expected, a milestone in the city-state’s net zero journey

QUT scientists create material to turn waste heat into clean power

Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health

Cosmic crime scene: White dwarf found devouring Pluto-like icy world

Major report tackles Covid’s cardiovascular crisis head-on

A third of licensed GPs in England not working in NHS general practice

ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle

Engineers uncover why tiny particles form clusters in turbulent air

GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Psoriasis linked to increased risk of vision-threatening eye disease, study finds

Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity

[Press-News.org] UBC-VCH scientists use drug to repair rare birth defect
Success in mouse model is first instance of drug reversing a congenital deformity